503 related articles for article (PubMed ID: 11772129)
1. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
2. Secondary hormonal manipulation of prostate cancer.
Small EJ; Harris KA
Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):24-30. PubMed ID: 12198635
[TBL] [Abstract][Full Text] [Related]
3. Secondary hormonal manipulation of prostate cancer.
Harris KA; Small EJ
Curr Urol Rep; 2001 Jun; 2(3):224-30. PubMed ID: 12084269
[TBL] [Abstract][Full Text] [Related]
4. Treatment options in hormone-refractory metastatic prostate carcinoma.
Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E
Tumori; 2004; 90(6):535-46. PubMed ID: 15762353
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
6. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.
Autorino R; Di Lorenzo G; Damiano R; De Placido S; D'Armiento M
Urol Int; 2003; 70(1):1-14. PubMed ID: 12566808
[TBL] [Abstract][Full Text] [Related]
7. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of prostate cancer. A review.
Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
[TBL] [Abstract][Full Text] [Related]
9. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
11. State-of-the-art treatment of metastatic hormone-refractory prostate cancer.
Goodin S; Rao KV; DiPaola RS
Oncologist; 2002; 7(4):360-70. PubMed ID: 12185298
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy in advanced prostate cancer.
Beedassy A; Cardi G
Semin Oncol; 1999 Aug; 26(4):428-38. PubMed ID: 10482185
[TBL] [Abstract][Full Text] [Related]
14. The role of systemic cytotoxic therapy for prostate cancer.
Chang SS; Kibel AS
BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
16. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Moore MA; Chang SJ; Cheng C; Choi HY; Esuvaranathan K; Hinotsu S; Hong SJ; Kim CS; Kim WJ; Murai M; Naito S; Soebadi D; Song JM; Umbas R; Usami M; Xia S; Yang CR
Asian Pac J Cancer Prev; 2007; 8(1):3-12. PubMed ID: 17477764
[TBL] [Abstract][Full Text] [Related]
17. Current treatment of advanced prostate cancer.
Ismail M; Gomella LG
Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
[TBL] [Abstract][Full Text] [Related]
18. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.
Winquist E; Waldron T; Berry S; Ernst DS; Hotte S; Lukka H
BMC Cancer; 2006 May; 6():112. PubMed ID: 16670021
[TBL] [Abstract][Full Text] [Related]
19. Drug development in prostate cancer.
Ripple GH; Wilding G
Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732
[TBL] [Abstract][Full Text] [Related]
20. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
